

# Orchazid SDU 0.25 mg/ml, eye drops, solution.

Summary of Product Characteristics

## 1. Name of the medicinal product

Orchazid SDU 0.25 mg/ml, Sterile ophthalmic solution in single dose unit.

## 2. Qualitative and quantitative composition

One ml contains 0.345 mg ketotifen fumarate corresponding to 0.25 mg ketotifen.

Each drop contains 8.5 microgram ketotifen fumarate.

Excipient(s) with known effect: Benzalkonium chloride (0.1 mg/ml).

For the full list of excipients, see section 6.1.

## 3. Pharmaceutical form

Eye drops, solution.

Clear, colourless to faintly yellow solution.

## 4. Clinical particulars

### 4.1 Therapeutic indications

Symptomatic treatment of seasonal allergic conjunctivitis.

### 4.2 Posology and method of administration

Adults, elderly and children (age 3 and older): one drop of Orchazid into the conjunctival sac twice a day.

The contents and dispenser remain sterile until the original closure is broken.

To avoid contamination do not touch any surface with the dropper tip.

The safety and efficacy of Orchazid in children aged from birth to 3 years have not yet been established.

### 4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in Section 6.1.

### 4.4 Special warnings and precautions for use

There are no special warnings or precautions

### 4.5 Interaction with other medicinal products and other forms of interaction

If Orchazid is used concomitantly with other eye medications there must be an interval of at least 5 minutes between the two medications.

The use of oral dosage forms of ketotifen may potentiate the effect of CNS depressants, antihistamines and alcohol. Although this has not been observed with Orchazid eye drops, the possibility of such effects cannot be excluded.

### 4.6 Fertility, pregnancy and lactation

#### Pregnancy

There are no adequate data from the use of ketotifen eye drops in pregnant women. Animal studies using maternally toxic oral doses showed increased pre- and postnatal mortality, but no teratogenicity. Systemic levels after ocular administration are much lower than after oral use. Caution should be exercised when prescribing to pregnant women.

### Breast-feeding

Although animal data following oral administration show excretion into breast milk, topical administration to human is unlikely to produce detectable quantities in breast milk. Orcahizid eye drops can be used during lactation.

### Fertility

There are no data available on the effect of ketotifen fumarate on fertility in humans.

## **4.7 Effects on ability to drive and use machines**

Any patient who experiences blurred vision or somnolence should not drive or operate machines.

## **4.8 Undesirable effects**

Adverse reactions are ranked under heading of frequency, using the following convention: Very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); very rare ( $< 1/10,000$ ), not known (cannot be estimated from the available data).

### Immune system disorders

Uncommon: Hypersensitivity

### Nervous system disorders

Uncommon: Headache

### Eye disorders

Common: Eye irritation, eye pain, punctate keratitis, punctate corneal epithelial erosion.

Uncommon: Vision blurred (during instillation), dry eye, eyelid disorder, conjunctivitis, photophobia, conjunctival haemorrhage.

### Gastrointestinal disorders

Uncommon: Dry mouth

### Skin and subcutaneous tissue disorders

Uncommon: Rash, eczema, urticarial

### General disorders and administration site conditions

Uncommon: Somnolence

Adverse drug reactions from post-marketing experience (Frequency not known):

The following post marketing events have also been observed: hypersensitivity reactions including local allergic reaction (mostly contact dermatitis, eye swelling, eyelid pruritis and oedema), systemic allergic reactions including facial swelling/oedema (in some cases associated with contact dermatitis) and exacerbation of pre-existing allergic conditions such as asthma and eczema.

## **4.9 Overdose**

No case of overdose has been reported.

Oral ingestion of the contents of a 5ml bottle would be equivalent to 1.25mg of ketotifen which is 60% of a recommended oral daily dose for a 3 year old child. Clinical results have shown no serious signs or symptoms after oral ingestion of up to 20mg of ketotifen.

## **5. Pharmacological properties**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Ophthalmologicals, other antiallergics

Ketotifen is a histamine H1-receptor antagonist. In vivo animal studies and in vitro studies suggest the additional activities of mast cell stabilisation and inhibition of infiltration, activation and degranulation of eosinophils.

### **5.2 Pharmacokinetic properties**

In a pharmacokinetic study conducted in 18 healthy volunteers with Orchazid eye drops, plasma levels of ketotifen after repeated ocular administration for 14 days were in most cases below the limit of quantitation (20pg/ml).

After oral administration, ketotifen is eliminated biphasically with an initial half-life of 3 to 5 hours and a terminal half-life of 21 hours. About 1% of the substance is excreted unchanged in the urine within 48 hours and 60 to 70% as metabolites. The main metabolite is the practically inactive ketotifen-Nglucuronide.

### **5.3 Preclinical safety data**

Preclinical data reveal no special hazard which is considered relevant in connection with use of Orchazid eye drops in humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.

## **6. Pharmaceutical particulars**

### **6.1 List of excipients**

Glycerol

Sodium Citrate

Citric acid

Sodium hydroxide/

hydrochloric acid

Water for injections

### **6.2 Incompatibilities**

Not applicable.

### **6.3 Shelf life and storage**

Store at temperature not exceeding 30°C before opening and after opening, the remaining amount discarded directly after use.

### **6.5 Nature and contents of container**

Carton box containing 30 units of LDPE ( Low density polypropylene) plastic bottle containing 0.4 ml solution + inner leaflet.

### **6.6 Special precautions for disposal and other handling**

No special requirements.

## **7. Marketing authorisation holder**

Orchidia pharmaceutical industries

**8. Marketing authorisation number(s)**

32870/2018

**9. Date of first authorisation/renewal of the authorisation**

11/10/2018 11/10/2021

**10. Date of revision of the text**

15/01/2019

**Company Contact Details**

Orchidia pharmaceutical industries

**Address**

Al Obour City- North industrial zone extension,  
parts no. (14,15) Block no. 12011 Cairo, Egypt.

**Telephone:** + 202 4489 15 80

**Fax:** +202 4489 12 35

**www.Orchidiapharma.com**